Clinical Trial Update: Safety and Efficacy Study of GM-CSF, Thalidomide Plus Docetaxel in Prostate Cancer [Phase 2]

View source ↗

Summary

This Phase 2 trial evaluated GM-CSF, thalidomide, and docetaxel in prostate cancer and has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• GM-CSF (granulocyte-macrophage colony-stimulating factor)
• Thalidomide (thalidomide)

Snippet

Sponsor: The Methodist Hospital Research Institute | Conditions: Prostatic Neoplasms | Phase 2 | Status: TERMINATED